K Reach Chemical Registration Services In South Korea

Scope and evidence must be confirmed before any paid tests or filings.

K-REACH filing is not a generic product certificate. For a specific chemical substance, the work starts by confirming identity, annual Korean manufacture/import volumes, legal applicant and the correct registration, notification or exemption-confirmation pathway. A consultant can assemble and track a dossier but does not replace the applicant's legal duties.

Under the Korean Act on the Registration and Evaluation of Chemical Substances, effective as amended on 12 May 2026, the ordinary registration threshold for both new and existing substances is 1 tonne per year. New substances below 1 tonne generally follow a pre-manufacture/import notification route. Existing-substance deferrals are conditional, not automatic permission to sell.

Which filing route should the project use?

Lock the route per substance and per responsible entity before commissioning tests. The table is a triage tool, not an exemption determination. For existing substances, the 2021 deadline for designated CMR substances at 1 t/year or more and the 1,000 t/year band, and the 2024 deadline for 100 to less than 1,000 t/year, have already passed. The 2027/2030 bands require valid prior declarations.

Situation	Filing decision
New substance, at least 1 t/year	Register before Korean manufacture/import under Article 10(1); confirm whether a special rule affects the substance.
New substance, below 1 t/year	Generally notify before manufacture/import under Article 10(4); do not mistake notification for full registration.
Existing substance, at least 1 t/year	Check valid existing-substance pre-notification, hazard designation, tonnage band and whether the registration grace period is still open.
Existing substance, below 1 t/year	Article 10(1)'s ordinary tonnage threshold is not met, but check specially designated substances and other applicable duties.
Potential Article 11 exclusion/exemption	Identify the precise statutory category; some routes require an affirmative exemption-confirmation decision before relying on them.

Article 11 draws an important distinction: the statutory categories in Article 11(1)(1)–(2) do not require the exemption-confirmation decision specified for Article 11(1)(3). The latter requires the formal confirmation under Article 11(2). Document why the actual substance and activity qualify before relying on either route.

Who files and who supplies the evidence?

A Korean manufacturer or importer normally controls its own filing. Under Article 38, a foreign manufacturer/producer may appoint a qualifying Korean representative to perform specified filings instead of an importer; appointment/dismissal must be reported, and prescribed information must be communicated to importers. An ordinary consultant is not automatically that representative.

Applicant or appointed representative: signs off on identity, volume, covered importers, statements, submission and authority correspondence.
Foreign producer and downstream users: supply composition, impurity profile, use patterns, exposure and credible test/data rights; agree confidentiality boundaries.
Filing consultant: checks route, constructs evidence matrix, manages joint-submission/data-access work, tracks questions and delivers an auditable filing record; responsibility cannot be delegated merely by a service contract.

What belongs in a registration dossier?

Article 14 and the official registration service describe a substance-specific package. The final data set depends on route, tonnage, applicable waivers and authorized data access; not every bullet is a mandatory study for every applicant.

Legal-entity details and representative/appointment evidence, if applicable.
Substance identity: name, formula/structure, composition and impurity evidence adequate to distinguish the substance from nearby identifiers.
Uses, intended Korean tonnage, hazard classification and labelling rationale.
Physicochemical and hazard study records with test identity, quality and right-to-use evidence; check statutory laboratory/test rules.
Exposure/use information, safe-use instructions and, at 10 t/year or more where required, lifecycle risk information including exposure scenarios.
Joint-submission or separate-submission basis, justified omission/test-plan documents and confidentiality request where applicable.

Keep a dossier index stating for each item: source, owner, version, gap, proposed remedy and whether it is filed or merely kept internally.

For a new-substance notification under Article 10(4), do not treat the full registration checklist above as automatically required. Article 14(6) instead specifies applicant, substance, use and classification/labelling information (including the classification rationale), plus documents prescribed by the Enforcement Rule, including relevant data already held by the notifier. Check the current notification form separately before ordering registration-level studies.

The six-step submission and authority-response workflow

The deliverable is a traceable filing, not simply a folder of SDS documents.

When registering an existing substance during an applicable statutory grace period, Article 15 generally requires separate applications by each registrant but joint submission of prescribed core data through a selected lead; individual submission requires confirmation of a qualifying statutory ground. The current Enforcement Rule identifies classification/labelling, physicochemical and hazard data, and relevant test plans as joint data. Check consortium status, evidence rights and a documented cost arrangement before setting the filing date.

For existing substances registered within an applicable grace period, amended Article 15 also requires a joint-submission consortium and a representative. Article 16-2 establishes fair, transparent and non-discriminatory principles for the parties’ agreed cost sharing and data-use charges. Where a dispute threatens registration, Article 16-3 provides a formal mediation route; negotiations or a mediation request alone do not grant permission to import.

Freeze identity and volumes: obtain substance identifiers, composition, Korean importers, forecast bands and current registration/pre-notification history.
Make a written route decision: record Article 10/11 tests, any Article 38 appointment and whether a grace period or special designation changes timing.
Clear data rights and gaps: investigate existing registrations and joint-submission arrangements; document permission to cite studies before paying for unnecessary new tests.
Assemble the application: reconcile uses, classification, hazard endpoints, exposure, safe-use and supporting documents against the applicable forms.
Submit through the official K-REACH electronic channel or the competent accepted channel; retain the filing reference, submitted version and payment/receipt evidence.
Manage review: assign and answer requests for correction or extra evidence, record the authority outcome/notification and release imports only against the confirmed legally applicable status.

Submission is not the same as acceptance. Under Article 10(7), the authority decides and notifies whether registration or notification is accepted. Retain that outcome, or documentary proof of a currently applicable existing-substance deferral, before concluding that a supply route is lawful; a portal upload receipt by itself is insufficient.

Four delays to solve before pressing submit

These are practical failure modes, not a published list of automatic statutory rejection grounds.

Risk signal	Preventive control
CAS/name matches, composition does not	Reconcile substance identity and impurities with supplier records before choosing a joint dossier.
Pre-notification assumed but not evidenced	Retrieve the substance/applicant filing record and verify grace-period conditions; past deadlines cannot be revived by a consultant's assertion.
Study is available but not legally usable	Check ownership, letter of access, laboratory qualification and endpoint relevance; document the permission.
A change is described in email but not in the submitted file	Maintain one controlled dossier version and a regulator-question log with accountable owners.

After the filing: keep registration coverage current

Registration is a continuing record of the actual applicant, substance and covered activity, not an unqualified blanket approval.

Monitor annual tonnage bands and newly planned Korean uses against the registered scope.
Screen relevant changes under Article 12: some require change registration, while other changes require notification; exact triggers depend on the change and implementing rules.
Keep the registration/notification notice, submission package, data-access terms and history of official correspondence retrievable.
If representative, producer, importer or composition arrangements change, evaluate filing continuity before shipment; do not assume a registration can simply be transferred.

If a foreign producer replaces its appointed representative, Article 45-2(2) and (4), effective from 12 May 2026, provides for succession to the effect of the former representative’s statutory filings with the new representative’s consent. The new representative must report the succession within one month of appointment, using the prescribed evidence. Check the predecessor’s filing history and importer coverage; a private change of service provider alone does not complete this procedure.

K-REACH substance filings versus Korean product approvals

This article addresses preparation, submission and maintenance of a substance filing. It does not determine all product-level regimes, such as KC certification or medical-device approvals. For broader Korean regulatory routing, see Korean product-compliance and market-access overview. For a separate certification workstream, see KC certification advisory. EU REACH evidence is potentially useful but does not itself complete a Korean filing.

The first safe instruction to a consultant is: “Confirm my applicant, substance identity, tonnage, existing Korean filing status and documentary data rights; then provide the filing route, gap log and responsibility matrix before proposing tests.”

Official K-REACH provisions and filing services

Korean Act (Articles 10–14 and 38); current Presidential Decree (Article 10); Government24 registration and new-substance notification services; Government24 exemption-confirmation service.

K-REACH filing questions that change the decision

Answers depend on the actual substance, applicant and file history.

Can an EU REACH registration number replace the Korean filing?: No. EU evidence may support endpoint analysis subject to lawful use, but applicant, route and Korean submission must be assessed separately.
Does my 500 kg/year new chemical need no action?: Not by tonnage alone. Article 10(4) generally requires notification below 1 tonne, subject to applicable statutory exceptions or a confirmed exemption route.
Can a foreign supplier file without naming a Korean importer?: Article 38 permits a qualifying appointed representative in specified circumstances; importer coverage, appointment reporting and the file's scope still require verification.
We pre-notified an existing chemical: may we keep importing until 2030?: Not necessarily. For 10 to less than 100 t/year the ordinary deferral ends 31 December 2027; for 1 to less than 10 t/year it ends 31 December 2030. Eligibility and other designated-substance rules must be checked.
Can the consultant reuse a competitor's toxicology study?: Not merely because a report exists. Verify study access and the Korean joint/data-sharing procedure; otherwise commission or justify lawful alternative evidence.